A token buy at best. Considering directors didn't participate in the CR and the share price dropped below the CR price, it was inevitable that the token director buy was going to come
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025